Affiliation:
1. Department of Technology and Design Thinking for Medicine, Hiroshima University, Hiroshima 734-0037, Japan
2. Department of Ophthalmology, Tsukazaki Hospital, Himeji 671-1227, Japan
3. Department of Ophthalmology, Nagoya City University, Nagoya 467-0001, Japan
Abstract
(1) Background: Age-related Macular Degeneration (AMD) is a critical condition leading to blindness, necessitating lifelong clinic visits for management, albeit with existing challenges in monitoring its long-term progression. This study introduced and assessed an innovative tool, the AMD long-term Information Viewer (AMD VIEWER), designed to offer a comprehensive display of crucial medical data—including visual acuity, central retinal thickness, macular volume, vitreous injection treatment history, and Optical Coherent Tomography (OCT) images—across an individual eye’s entire treatment course. (2) Methods: By analyzing visit frequencies of patients with a history of invasive AMD treatment, a comparative examination between a Dropout group and an Active group underscored the clinical importance of regular visits, particularly highlighting better treatment outcomes and maintained visual acuity in the Active group. (3) Results: The efficiency of AMD VIEWER was proven by comparing it to manual data input by optometrists, showing significantly faster data display with no errors, unlike the time-consuming and error-prone manual entries. Furthermore, an elicited Net Promoter Score (NPS) of 70 from 10 ophthalmologists strongly endorsed AMD VIEWER’s practical utility. (4) Conclusions: This study underscores the importance of regular clinic visits for AMD patients. It suggests the AMD VIEWER as an effective tool for improving treatment data management and display.
Reference22 articles.
1. Prospective, multi-site study of patient outcomes after implementing the TREWS machine learning-based early warning system for sepsis;Adams;Nat. Med.,2022
2. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration;Li;Cochrane Database Syst. Rev.,2020
3. GBD 2019 Blindness, Vision Impairment Collaborators, and Vision Loss Expert Group of the Global Burden of Disease Study (2021). Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The right to sight: An analysis for the global burden of disease study. Lancet Glob. Health, 9, e144–e160.
4. Adherence to Intravitreal Anti-Vascular Endothelial Growth Factor (Anti-VEGF) drugs in diabetic macular edema in an egyptian population: A health belief model;Habib;Curr. Eye Res.,2019
5. The effects of amount of information provided and feedback of results on decision making efficiency;Hammer;Hum. Factors,1965